Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Immunoprecise Antibodies Ltd
IPA
Healthcare
Biotechnology
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem...
Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:IPA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 29, 2022 8:08am
New Press Release - Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope's Efficacy Against SARS-CoV-2 Variants Including BA.5
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), a biotherapeutic research and technology company, today announced the continuing success of PolyTope® TATX-03 antibody combination therapy to neutralize variants of concern of the COVID-19 causative virus...
read article.
(54)
•••
GoldenArm
X
View Profile
View Bullboard History
Comment by
GoldenArm
on Aug 18, 2022 8:54am
RE:stock on fire/ insiders are still loading
We can only hope that the enthuasim for the stock comes back as they continue to prove that Polytope vaccines are Super effective especially when considering Coronavirus mutations. This tech can be
...more
(17)
•••
Vancgatekeeper
X
View Profile
View Bullboard History
Post by
Vancgatekeeper
on Aug 17, 2022 6:37pm
stock on fire/ insiders are still loading
Massive buy under $10, something big is brewing, stock above all MDAs. SEPT TO REMEMBER! Targets 15-25 Sept / 30 plus before 2023
(54)
•••
GoldenArm
X
View Profile
View Bullboard History
Comment by
GoldenArm
on Aug 17, 2022 3:02pm
RE:IPA insiders are loading and stock closing above all MDAs
Under $8 gone. Load up under $10. I said something was up. Insider buying could mean something big. Potential of this company goning to $100'shr soon is a definitely non-zero. Might be a bit of an
...more
(22)
•••
wallpaper2
X
View Profile
View Bullboard History
Comment by
wallpaper2
on Aug 16, 2022 5:11pm
RE:IPA insiders are loading and stock closing above all MDAs
Up almost 50% the past few weeks. I'd hate to have shorted this puppy.
(17)
•••
Vancgatekeeper
X
View Profile
View Bullboard History
Post by
Vancgatekeeper
on Aug 13, 2022 4:29pm
IPA insiders are loading and stock closing above all MDAs
Big insider buys plus chart is prime for another 2020 run. Closes over 200 this week is great signal of new bull run. Load up under $8!!!! Target $20-30 before 2023.
(742)
•••
mercedesman
X
View Profile
View Bullboard History
Comment by
mercedesman
on Aug 12, 2022 4:44pm
RE:RE:RE:RE:ImmunoPrecise Reports Financial Results and Recent Business
Actually volume has fallen off a cliff in the past year or so...and remains light. Insider accumulation has been non-stop for most of the past year. As some deals from their pipeline come to
...more
(54)
•••
GoldenArm
X
View Profile
View Bullboard History
Comment by
GoldenArm
on Aug 12, 2022 1:14pm
RE:RE:RE:ImmunoPrecise Reports Financial Results and Recent Business
100% agree on that on big sale of Tatx going to phase 3. Don't know if this is all insider buying but can't say it it is not. Volume is up big time today.
(742)
•••
mercedesman
X
View Profile
View Bullboard History
Comment by
mercedesman
on Aug 12, 2022 11:10am
RE:RE:ImmunoPrecise Reports Financial Results and Recent Business
Steady Insider buying since the start of 2022. Bath has more tripled her position since Dec 31 2021. Lots of other (smaller) buys from other Officers & Directors. I doubt there is NEWS that is
...more
(54)
•••
GoldenArm
X
View Profile
View Bullboard History
Post by
GoldenArm
on Aug 12, 2022 10:33am
There has got to be news coming
Volume has picked up and because there aren't too many shares available for trade the stock is moved up significantly. Anyone got anything?
(54)
•••
GoldenArm
X
View Profile
View Bullboard History
Comment by
GoldenArm
on Aug 11, 2022 12:47pm
RE:ImmunoPrecise Reports Financial Results and Recent Business
Something is up here. There has been buying for the last 5 days. If the company has news they should release it now. Can someone see if this is insider buying? I would do it but I'm swamped at
...more
(2)
•••
AveragePenny
X
View Profile
View Bullboard History
Post by
AveragePenny
on Jul 29, 2022 11:38am
ImmunoPrecise Reports Financial Results and Recent Business
Fiscal 2022 Financial Summary* The Company achieved record total revenues of $19.4 million during the year ended April 30, 2022, an 8.1% increase from the year ended April 30, 2021. Project
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 29, 2022 8:07am
New Press Release - ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
The Company achieved record revenues of $19.4 million, up 8.1% from $17.9 million in fiscal year 2021The Company achieved record revenues of $5.2 million for the three months ended April 30, 2022, an increase of 7.4% over the same period last year.The Company achieved an increase in CRO revenue...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 26, 2022 8:15am
New Press Release - IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
The Company to host an earnings conference call via webcast IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its financial results...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.
Growth Rocket 2025 – Why dynaCERT is in the Spotlight